WallStreetZenWallStreetZen

NASDAQ: PSTV
Plus Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Plus Therapeutics revenue was $5.82M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $1.4M, down 3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PSTV annual revenue was $5.8M, with 18.5% growth year-over-year.

PSTV past revenue growth

How has PSTV's revenue growth performed historically?

Company
18.54%
Industry
511.06%
Market
20.87%
PSTV's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
PSTV's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
PSTV's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

PSTV revenue history

Current Revenue
$5.8M
Current Earnings
-$13.0M
Current Profit Margin
-222.8%

Be the first to know when PSTV announces revenue.

PSTV Revenue History By Year

PSTV Yearly RevenuePSTV RevenuePSTV ChangePSTV Revenue Growth
2024-12-31$5.82M$911.00k+18.54%
2023-12-31$4.91M$4.69M+2,093.30%
2022-12-31$224.00kN/AN/A
2021-12-31$0.00-$303.00k-100.00%
2020-12-31$303.00k-$6.70M-95.67%
2019-12-31$7.00M$4.02M+134.60%
2018-12-31$2.98M-$3.43M-53.47%
2017-12-31$6.41M-$4.97M-43.66%
2016-12-31$11.38M-$279.00k-2.39%
2015-12-31$11.66M$4.06M+53.45%
2014-12-31$7.60M-$4.60M-37.70%
2013-12-31$12.20M-$2.31M-15.90%
2012-12-31$14.50M$4.51M+45.07%
2011-12-31$10.00M-$631.00k-5.94%
2010-12-31$10.63M-$4.10M-27.85%
2009-12-31$14.73M$7.88M+114.94%
2008-12-31$6.85M$804.00k+13.29%
2007-12-31$6.05M-$1.88M-23.69%
2006-12-31$7.93M$1.92M+32.01%
2005-12-31$6.01M-$813.00k-11.92%
2004-12-31$6.82M-$7.27M-51.60%
2003-12-31$14.09M$4.92M+53.70%
2002-12-31$9.17M$3.52M+62.29%
2001-12-31$5.65M-$603.00k-9.65%
2000-12-31$6.25M$4.74M+313.15%
1999-12-31$1.51MN/AN/A
1998-12-31$0.00N/AN/A

1 of 2

Plus Therapeutics Revenue FAQ

What was PSTV's revenue last quarter?

On Invalid Date, Plus Therapeutics (NASDAQ: PSTV) reported Q4 2024 revenue of $1.41 million up 7.54% year over year. In the same quarter last year, Plus Therapeutics's revenue was $1.31 million.

What was Plus Therapeutics's revenue in 2024?

Plus Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $5.82 million, a 18.54% increase year over year.

How much does Plus Therapeutics make in a day?

Based on Plus Therapeutics annual revenue for the past five years, PSTV makes an average of $6,172.05 per day.

What was Plus Therapeutics's annual revenue growth in the past year?

As of Q2 2025, Plus Therapeutics's revenue has grown 18.54% year over year. This is 492.52 percentage points lower than the US Biotechnology industry revenue growth rate of 511.06%. Plus Therapeutics's revenue in the past year totaled $5.82 million.

How much does Plus Therapeutics make in a year?

Plus Therapeutics's revenue by year for the past five years is:
  • Plus Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $5.82 million, a 18.54% increase year over year.
  • Plus Therapeutics's annual revenue for Dec 31, 2023 was $4.91 million, a 2,093.3% increase from 2022.
  • Plus Therapeutics's annual revenue for 2022 was $224.00 thousand, a Infinity% increase from 2021.
  • Plus Therapeutics's annual revenue for 2021 was $0.00, a 100% decrease from 2020.
  • Plus Therapeutics's annual revenue for 2020 was $303.00 thousand, a 95.67% decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.